Categories

News

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
2026-08-03
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.
"BMS Unleashes Life Sciences' Most Powerful AI Supercomputer with NVIDIA's Next-Gen Rubin GPUs"
2026-07-29
Bristol Myers Squibb is deploying an NVIDIA DGX SuperPOD with eight Vera Rubin NVL72 racks (576 Rubin GPUs), claiming it as life sciences' most powerful single-owned AI infrastructure. This follows Lilly's October 2025 supercomputer and Roche's March 2026 AI factory. BMS, which has operated a DGX SuperPOD since 2024, is expanding and combining systems. The new cluster offers ~10.1 exaflops peak dense FP8 training performance and 166 TB memory.
FDA approves Freenome's blood test for colorectal cancer screening
2026-07-28
The U.S. FDA has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer in adults aged 45 and older—the company's first commercial product. Partner Abbott will exclusively commercialize it in the U.S. starting this fall, competing with Guardant Health's Shield test. The test detects cancer signals from circulating DNA fragments. In a 48,000-person study, it showed 81.1% sensitivity for colorectal cancer and 13.7% for advanced precancerous growths
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
2026-07-27
Roche received FDA 510(k) clearance for its cobas® BV/CV assay, a molecular diagnostic test that detects Bacterial vaginosis and Candida vaginitis from a single vaginal swab. Traditional methods like microscopy have nearly 50% misdiagnosis rates. The PCR-based test improves accuracy, aligning with CDC guidelines. It integrates with Roche's sexual-health portfolio, enabling concurrent STI testing from one sample. Bacterial vaginosis affects ~27% of North American women of reproductive age.
Seegene USA Receives FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions
2026-07-23
Bristol Myers Squibb (BMS) will deploy NVIDIA’s Vera‑Rubin‑based DGX SuperPOD with 576 Rubin GPUs, becoming the first life‑science firm adopting Rubin‑generation infrastructure. This new cluster will merge with BMS’s existing SuperPOD to form a unified global compute environment. Compare with peers: Eli Lilly’s LillyPod runs 1016 Blackwell‑Ultra B300 GPUs, while Roche operates over 3500 total Blackwell‑family GPUs in hybrid‑cloud setup. Rubin delivers substantially higher energy‑efficiency than
Initiatives Look to Strengthen Vaccine Policy and Governance in US
2026-06-23
Two new complementary initiatives from CIDRAP’s Vaccine Integrity Project and The Evidence Collective aim to evaluate and improve US vaccine policymaking, governance, and public trust amid ongoing changes to the nation's immunization infrastructure.
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
2026-04-30
Over the past 16 months, Chinese biotechs have featured in ~6 of every 26 major pharma deals, accounting for nearly one-third of total value. Major licensing pacts include Merck with Hansoh and Hengrui, Pfizer with 3SBio, AstraZeneca with CSPC (twice), AbbVie with RemeGen, Sanofi with Sino Biopharm, and Lilly with Insilico. In 2025, China led global new drug launches for the first time, surpassing the U.S. McKinsey cites China’s R&D speed and cost advantages...
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
2026-04-02
According to the 2025 Pharma 50 ranking, Eli Lilly narrowly overtook Merck & Co. as the top‑ranked pharma firm by FY2025 pharma revenue, driven largely by tirzepatide. The dual GIP/GLP‑1 agonist beat semaglutide in the SURMOUNT‑5 head‑to‑head obesity trial published in NEJM, achieving 20.2% average weight loss versus 13.7%. Lilly captured two‑thirds of U.S. obesity‑medication patients by mid‑2025 despite Novo Nordisk’s early‑mover advantage with semaglutide‑based products Ozempic and Wegovy.
Go to page
CONTACT US
Name *
Email *
Message *
Verification code *
Click to verify